Modeling the hepatitis A epidemiological transition in Brazil and Mexico.

Abstract:

BACKGROUND:Many low- to middle-income countries have completed or are in the process of transitioning from high or intermediate to low endemicity for hepatitis A virus (HAV). Because the risk of severe hepatitis A disease increases with age at infection, decreased incidence that leaves older children and adults susceptible to HAV infection may actually increase the population-level burden of disease from HAV. Mathematical models can be helpful for projecting future epidemiological profiles for HAV. METHODS:An age-specific deterministic, dynamic compartmental transmission model with stratification by setting (rural versus urban) was calibrated with country-specific data on demography, urbanization, and seroprevalence of anti-HAV antibodies. HAV transmission was modeled as a function of setting-specific access to safe water. The model was then used to project various HAV-related epidemiological outcomes in Brazil and in Mexico from 1950 to 2050. RESULTS:The projected epidemiological outcomes were qualitatively similar in the 2 countries. The age at the midpoint of population immunity (AMPI) increased considerably and the mean age of symptomatic HAV cases shifted from childhood to early adulthood. The projected overall incidence rate of HAV infections decreased by about two thirds as safe water access improved. However, the incidence rate of symptomatic HAV infections remained roughly the same over the projection period. The incidence rates of HAV infections (all and symptomatic alone) were projected to become similar in rural and urban settings in the next decades. CONCLUSION:This model featuring population age structure, urbanization and access to safe water as key contributors to the epidemiological transition for HAV was previously validated with data from Thailand and fits equally well with data from Latin American countries. Assuming no introduction of a vaccination program over the projection period, both Brazil and Mexico were projected to experience a continued decrease in HAV incidence rates without any substantial decrease in the incidence rates of symptomatic HAV infections.

journal_name

Hum Vaccin Immunother

authors

Van Effelterre T,Guignard A,Marano C,Rojas R,Jacobsen KH

doi

10.1080/21645515.2017.1323158

subject

Has Abstract

pub_date

2017-08-03 00:00:00

pages

1942-1951

issue

8

eissn

2164-5515

issn

2164-554X

journal_volume

13

pub_type

杂志文章
  • A recombinant multi-epitope protein MEP1 elicits efficient long-term immune responses against HIV-1 infection.

    abstract::The effective protective HIV vaccine should elicit either protective antibodies or effective T cell response, or both. To improve the efficacy of HIV-1 vaccines, HLA polymorphism and HIV-1 diversity are 2 key factors to be considered for vaccine development. In this study, we expressed a recombinant multi-epitope prot...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1281488

    authors: Yang Y,Zhu Q,Sun W,Guo J,Ning X,Li Q,Guo Y,Li J,Kou Z,Zhou Y

    更新日期:2017-06-03 00:00:00

  • Timeliness of vaccination in infants followed by primary-care pediatricians in France.

    abstract::Vaccination status is more often evaluated by up-to-date vaccination coverage rather than timeliness of immunization. Delaying vaccination may be dangerous during infancy. The aim of this study was to identify the importance of potentially dangerous vaccination delay (previously defined) and determinants of these dela...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1409318

    authors: Bailly AC,Gras P,Lienhardt JF,Requillart JC,Vié-le-Sage F,Martinot A,Dubos F

    更新日期:2018-04-03 00:00:00

  • Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials.

    abstract::The objective of this analysis was to compare the anti-HPV GMTs and their distribution after a 6-month or a 3-8 -y interval between two HPV vaccine doses. The results from two clinical trials, conducted by the same team in the same region, with serological assays performed at the same laboratory using the same ELISA m...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1080/21645515.2019.1605278

    authors: Gilca V,Sauvageau C,Panicker G,De Serres G,Schiller J,Ouakki M,Unger ER

    更新日期:2019-01-01 00:00:00

  • Novel Coronavirus disease 2019 (COVID-19): new challenges and new responsibilities in developing countries.

    abstract::Novel coronavirus disease 2019 (COVID-19) is caused by the SARS-CoV-2 virus, which belongs to the genus Coronaviridae with its high mutation rate. From the current perspective, we discuss the current status of COVID-19, new challenges, and potential interventions to control the pandemic in developing counties such as ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1766939

    authors: Anjum FR,Anam S,Rahman SU

    更新日期:2020-10-02 00:00:00

  • Post-marketing surveillance of adverse events following measles, mumps, rubella and varicella (MMRV) vaccine: retrospecive study in apulia region (ITALY), 2009-2017.

    abstract::Since 2006, some Italian Regions introduced the active offer of measles, mumps, rubella, and varicella (MMRV) vaccine for all newborns during the second years of life. In 2011, Italian Drug Authority (AIFA) recommended the discontinuation of the MMRV use for an increased risk of febrile seizures following vaccination;...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2019.1704124

    authors: Stefanizzi P,De Nitto S,Patano F,Bianchi FP,Ferorelli D,Stella P,Ancona D,Bavaro V,Tafuri S

    更新日期:2020-08-02 00:00:00

  • Introduction of a new Rotavirus vaccine: Initial results of uptake and impact on laboratory confirmed cases in Anglia and Essex, United Kingdom, July 2015.

    abstract::Rotavirus gastroenteritis accounts for an estimated 130,000 GP consultations and 13,000 hospitalisations for children under 5 y old each year in England and Wales. In July 2013, an oral live attenuated rotavirus vaccine (Rotarix®) was introduced into the UK infant immunisation program as a 2 dose schedule at 2 and 3 m...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2015.1108501

    authors: Inns T,Trindall A,Dunling-Hall S,Shankar AG

    更新日期:2016-04-02 00:00:00

  • Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses.

    abstract::There is a need for both new and improved vaccination formulations for a range of diseases for which current vaccines are either inadequate or non-existent. Biodegradable polymer-based vaccines fulfill many of the desired properties in achieving effective long-term protection in a manner that is safe, economical, and ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/hv.26136

    authors: Joshi VB,Geary SM,Salem AK

    更新日期:2013-12-01 00:00:00

  • Passive immunization for the public health control of communicable diseases: current status in four high-income countries and where to next.

    abstract::The practice of passive immunization with human immune globulin (IG) for the control of communicable diseases (measles, rubella and hepatitis A) differs somewhat between Australia, the United States of America, the United Kingdom, and New Zealand despite the many similarities of these countries, including disease inci...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/hv.25311

    authors: Young MK,Cripps AW

    更新日期:2013-09-01 00:00:00

  • Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.

    abstract::Despite the impressive impact of vaccines on public health, the success of vaccines targeting many important pathogens and cancers has to date been limited. The burden of infectious diseases today is mainly caused by antigenically variable pathogens (AVPs), which escape immune responses induced by prior infection or v...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2016.1191718

    authors: Servín-Blanco R,Zamora-Alvarado R,Gevorkian G,Manoutcharian K

    更新日期:2016-10-02 00:00:00

  • Purification and immunogenicity of hemagglutinin from highly pathogenic avian influenza virus H5N1 expressed in Nicotiana benthamiana.

    abstract::Highly pathogenic avian influenza (HPAI) H5N1 is an ongoing global health concern due to its severe sporadic outbreaks in Asia, Africa and Europe, which poses a potential pandemic threat. The development of safe and cost-effective vaccine candidates for HPAI is considered the best strategy for managing the disease and...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1264783

    authors: Pua TL,Chan XY,Loh HS,Omar AR,Yusibov V,Musiychuk K,Hall AC,Coffin MV,Shoji Y,Chichester JA,Bi H,Streatfield SJ

    更新日期:2017-02-01 00:00:00

  • Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial.

    abstract::Human papillomavirus (HPV) vaccines are efficacious against HPV infections and associated lesions in women HPV-naïve at vaccination. However, vaccine efficacy (VE) against oncogenic, high-risk HPV (HR-HPV) types in women infected with any other HR-HPV type at first vaccination (baseline) remains unclear. This post-hoc...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1829411

    authors: Hu S,Xu X,Zhu F,Hong Y,Hu Y,Zhang X,Pan Q,Zhang W,Zhang C,Yang X,Yu J,Zhu J,Zhu Y,Chen F,Zhao S,Karkada N,Tang H,Bi D,Struyf F,Zhao F

    更新日期:2020-11-12 00:00:00

  • Viral etiological causes of febrile seizures for respiratory pathogens (EFES Study).

    abstract:BACKGROUND:Febrile seizure is the most common childhood neurological disorder, is an important health problem with potential short- and long-term complications, also leading to economic burden and increased parental anxiety about fevers and seizures occurring in their children. There are no routine recommendation to de...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1080/21645515.2018.1526588

    authors: Carman KB,Calik M,Karal Y,Isikay S,Kocak O,Ozcelik A,Yazar AS,Nuhoglu C,Sag C,Kilic O,Dinleyici M,Lacinel Gurlevik S,Yimenicioglu S,Ekici A,Perk P,Tosun A,Isik I,Yarar C,Arslantas D,Dinleyici EC

    更新日期:2019-01-01 00:00:00

  • Rubella vaccine: new horizon in prevention of congenital rubella syndrome in the India.

    abstract::Rubella is a contagious viral disease, which mainly affects the fetus, if the mother is infected in the 1st trimester of her pregnancy. All adolescent girls (aged 11 to 19 y) and women of childbearing age are at risk of developing rubella. This disease is mild and self-limiting, and incubation period is 2-3 weeks. Hum...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.19584

    authors: Verma R,Khanna P,Chawla S

    更新日期:2012-06-01 00:00:00

  • Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis.

    abstract::The prevalence of seasonal allergic rhinitis in the western world is high and increasing. Besides considerably affecting physical and psychosocial aspects of patients' lives, allergic rhinitis is often associated with allergic asthma and may aggravate this condition over time. Specific immunotherapy is currently the o...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.24631

    authors: Rosewich M,Lee D,Zielen S

    更新日期:2013-07-01 00:00:00

  • Noninvasive vaccination against infectious diseases.

    abstract::The development of a successful vaccine, which should elicit a combination of humoral and cellular responses to control or prevent infections, is the first step in protecting against infectious diseases. A vaccine may protect against bacterial, fungal, parasitic, or viral infections in animal models, but to be effecti...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/21645515.2018.1461296

    authors: Zheng Z,Diaz-Arévalo D,Guan H,Zeng M

    更新日期:2018-07-03 00:00:00

  • Novel dendritic cell-based vaccination in late stage melanoma.

    abstract::Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that play an important role in stimulating an immune response of both CD4(+) T helper cells and CD8(+) cytotoxic T lymphocytes (CTLs). As such, DCs have been studied extensively in cancer immunotherapy for their capability to induce a specific anti...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/hv.29110

    authors: Schneble EJ,Yu X,Wagner TE,Peoples GE

    更新日期:2014-01-01 00:00:00

  • Economic evaluation of Varicella vaccination: results of a systematic review.

    abstract:INTRODUCTION:The aim of the present study is to review the economic burden of varicella disease and the benefit of universal varicella vaccination in different settings pending its implementation in all Italian regions. MATERIALS AND METHODS:Research was conducted using PubMed, Scopus and ISI databases. Score quality ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/hv.25228

    authors: Unim B,Saulle R,Boccalini S,Taddei C,Ceccherini V,Boccia A,Bonanni P,La Torre G

    更新日期:2013-09-01 00:00:00

  • Influenza vaccination coverage rate in children: reasons for a failure and how to go forward.

    abstract::Based on an increasingly extensive literature expressing the large interest in the field, this paper gives an overview of different aspects of influenza prevention in children. It relies on paradoxes. First, the heaviest part of the burden is well demonstrated in the youngest infants by numerous epidemiological data e...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/hv.8.1.18278

    authors: Olivier CW

    更新日期:2012-01-01 00:00:00

  • Facilitators and barriers for use of rotavirus vaccine amongst various stakeholders and its implications for Indian context - A systematic review.

    abstract::Background: We performed a systematic review to evaluate factors affecting uptake of rotavirus vaccine amongst physicians, parents and health system. Methods: We identified 15 studies that met the inclusion criteria from 790 screened studies published between Jan 2005 to Jan 2016. Results: Perceived severity of rotavi...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1489190

    authors: Apte A,Roy S,Bavdekar A,Juvekar S,Hirve S

    更新日期:2018-01-01 00:00:00

  • Tetanus toxoid vaccine: elimination of neonatal tetanus in selected states of India.

    abstract::Tetanus is caused by a neurotoxin produced by Clostridium tetani (C. tetani), a spore-forming bacterium. Infection begins when tetanus spores are introduced into damaged tissue. Tetanus is characterized by muscle rigidity and painful muscle spasms caused by tetanus toxin's blockade of inhibitory neurons that normally ...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.4161/hv.21145

    authors: Verma R,Khanna P

    更新日期:2012-10-01 00:00:00

  • Mechanisms and pathways of innate immune activation and regulation in health and cancer.

    abstract::Research on innate immune signaling and regulation has recently focused on pathogen recognition receptors (PRRs) and their signaling pathways. Members of PRRs sense diverse microbial invasions or danger signals, and initiate innate immune signaling pathways, leading to proinflammatory cytokines production, which, in t...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/21645515.2014.979640

    authors: Cui J,Chen Y,Wang HY,Wang RF

    更新日期:2014-01-01 00:00:00

  • Vaccination against respiratory Pseudomonas aeruginosa infection.

    abstract::Respiratory infections caused by Pseudomonas aeruginosa are a major clinical problem globally, particularly for patients with chronic pulmonary disorders, such as those with cystic fibrosis (CF), non-CF bronchiectasis (nCFB) and severe chronic obstructive pulmonary disease (COPD). In addition, critically ill and immun...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/hv.34296

    authors: Grimwood K,Kyd JM,Owen SJ,Massa HM,Cripps AW

    更新日期:2015-01-01 00:00:00

  • HPV vaccine hesitancy among parents in Italy: a cross-sectional study.

    abstract::This cross-sectional survey determined the vaccine hesitancy related to Human papillomavirus (HPV) and the determinants among parents of adolescents aged 12 and 13 years in Italy. Data was collected through a self-administered questionnaire. Two-thirds of the parents (66.7%) had heard of HPV infection and knew that th...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1744367

    authors: Della Polla G,Pelullo CP,Napolitano F,Angelillo IF

    更新日期:2020-11-01 00:00:00

  • Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age.

    abstract::A 9-valent HPV (9vHPV) vaccine has been developed to protect against HPV type 6/11/16/18/31/33/45/52/58-related infection and disease. Previous safety analyses from 7 clinical trials conducted in 9vHPV vaccine recipients 9-26 years of age, including comparisons of 9vHPV and quadrivalent HPV (qHPV) vaccines in girls an...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1403700

    authors: Moreira ED,Giuliano AR,de Hoon J,Iversen OE,Joura EA,Restrepo J,Van Damme P,Vandermeulen C,Ellison MC,Krick A,Shields C,Heiles B,Luxembourg A

    更新日期:2018-02-01 00:00:00

  • The clinical, immunological and microbiological impact of the 10-valent pneumococcal-Protein D conjugate vaccine in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: A multi-centre, double-blind,

    abstract::We aimed to determine the efficacy of the 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in children aged 18-months to <18-years with recurrent protracted bacterial bronchitis (rPBB), chronic suppurative lung disease (CSLD) or bronchiectasis. In a multi-centre, double-blind randomi...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1488562

    authors: O'Grady KF,Chang AB,Cripps A,Mulholland EK,Smith-Vaughan H,Wood N,Danchin M,Thornton R,Wilson A,Torzillo PJ,Morris PM,Richmond P,Rablin S,Arnold D,Connor A,Goyal V,Stoney T,Perrett K,Grimwood K

    更新日期:2018-01-01 00:00:00

  • Parental vaccine attitudes, beliefs, and practices: initial evidence in California after a vaccine policy change.

    abstract::Senate Bill 277 (SB277) eliminated nonmedical exemptions for school-entry vaccines in California, but the impact of parental vaccine knowledge, attitudes, and beliefs on vaccine decision-making has not been extensively examined within the post-SB277 context. This study generates preliminary understanding and discussio...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2020.1839293

    authors: Holroyd TA,Howa AC,Delamater PL,Klein NP,Buttenheim AM,Limaye RJ,Proveaux TM,Omer SB,Salmon DA

    更新日期:2020-11-24 00:00:00

  • A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults.

    abstract::Neisseria meningitidis serogroup B (MnB) is a significant cause of invasive meningococcal disease, but no broadly protective vaccine is yet approved. We assessed the safety and immunogenicity of a bivalent MnB vaccine composed of lipidated subfamily A and B variants of recombinant LP2086 (rLP2086, also known as factor...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.4161/hv.19983

    authors: Sheldon EA,Schwartz H,Jiang Q,Giardina PC,Perez JL

    更新日期:2012-07-01 00:00:00

  • Intranasal immunization with a single dose of the fusion protein formulated with a combination adjuvant induces long-term protective immunity against respiratory syncytial virus.

    abstract::Respiratory syncytial virus (RSV) is the most common cause of respiratory tract infections in both children and elderly people. In this study we evaluated the short- and long-term protective efficacy of a single intranasal (IN) immunization with a RSV vaccine formulation consisting of a codon-optimized fusion (F) prot...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2017.1349584

    authors: Garg R,Latimer L,Gerdts V,Potter A,van Drunen Littel-van den Hurk S

    更新日期:2017-12-02 00:00:00

  • Sources of HPV vaccine hesitancy in parents.

    abstract::Despite strong national recommendations to vaccinate adolescents against the human papillomavirus (HPV), only 14% of teenage girls completed all 3 doses in 2010. Parental hesitancy may be one of the strongest reasons behind this low uptake rate. This review investigates sources of parental hesitancy including parental...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章,评审

    doi:10.4161/hv.26224

    authors: Patel PR,Berenson AB

    更新日期:2013-12-01 00:00:00

  • Safety of two doses of an inactivated hepatitis a vaccine given 6 months apart in healthy toddlers, children, and adolescents aged 12 months to 15 years in China: a phase IV study.

    abstract::Hepatitis A is a vaccine-preventable infection caused by the HA virus (HAV) with transitional to intermediate endemicity in China. An inactivated vaccine first licensed in China in 2010 (Avaxim® 80U Pediatric) is indicated for primary and booster vaccination in children from 12 months to 15 years of age. This Phase IV...

    journal_title:Human vaccines & immunotherapeutics

    pub_type: 杂志文章

    doi:10.1080/21645515.2018.1539600

    authors: Shi N,Rasuli A,Thollot Y

    更新日期:2019-01-01 00:00:00